Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. - Wikidata - awgldk - TriplyDB

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

http://www.wikidata.org/entity/Q37743107

about

Tumor molecular profiling of NSCLC patients using next generation sequencing.Yap regulates gastric cancer survival and migration via SIRT1/Mfn2/mitophagy.Precision Medicine for Heart Failure: Lessons From Oncology.The Akt pathway in oncology therapy and beyond (Review)

P2860

Q47710730-BDA55756-8010-4152-967A-A7597343E089 Q50047535-C51AA25B-CCEE-4BB6-8368-25499A9B039E Q55077633-602FBDFF-97DF-4D08-B91D-944F27E8BD6E Q58555910-85945D1A-68A8-4E84-9A1D-8C2795911014

P2860

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

http://www.wikidata.org/entity/Q37743107

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 April 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

@en

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

@nl

type

label

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

@en

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

@nl

prefLabel

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

@en

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

@nl

P1433

Q37743107-18F75298-1511-4FE0-A71E-1E6F8D23E633

P1476

Q37743107-B585A00D-2025-41EA-B6DF-D0746E25595A

P2093

Q37743107-51D2D40E-5590-4D31-A7A4-E6CB81263888

Q37743107-7B03E5C0-66A3-4EA4-9A98-CE999C353E81

Q37743107-E2756EDE-7EBB-49F8-8A5B-2F68E0F76441

P2860

Q37743107-05A02AD9-6E5D-4856-862F-694590DFEC52

Q37743107-06F1F6A8-F813-4CDB-B90A-FE13095E11A3

Q37743107-0D9DD232-E8E1-4752-99DF-5F55912DD341

Q37743107-0E92C1A9-2018-4EE8-8C4C-E110982994DB

Q37743107-0F28A400-92B0-4261-B4BF-012D9DF16B06

Q37743107-0F7F0BF2-1576-4B7F-8DA1-5DD5014C5EA7

Q37743107-11FC4D46-D262-47AC-AB22-1694D58C6FC2

Q37743107-168EB506-486F-484D-A42D-689CB71B93C1

Q37743107-16CCE5D4-2731-4AC5-9331-03216036B738

Q37743107-18E38BED-EAFD-4094-B330-94D6FA7DCAD7

P304

Q37743107-7AF530AC-6E62-443A-B4FD-5122DC694A86

P31

Q37743107-B70A6A4E-9FBE-4EDB-B81A-1E5731AA4ED6

P356

Q37743107-7A4D549A-E51E-4017-905D-29E7E2614DA8

P478

Q37743107-BFE7A6C3-F225-4AE0-8E6F-2269B9F5C39E

P50

Q37743107-201BB248-1A0E-4F04-8AB3-AA74FDC6D521

P577

Q37743107-D3E6627A-1DBA-4360-B726-4B8AF930F2B6

P698

Q37743107-0F1F9DD5-9227-421D-BEB0-B1E8838F3FE0

P932

Q37743107-74EDC074-5E3F-4FC0-BE41-2858003EB4CF

P356

FMED.2017.00039

P1433

Frontiers in medicine

P1476

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

@en

P2093

Dearbhaile Catherine Collins

http://www.w3.org/2001/XMLSchema#string

Maxime Chénard-Poirier

http://www.w3.org/2001/XMLSchema#string

Timothy A Yap

http://www.w3.org/2001/XMLSchema#string

P2860

An overview of the NCI precision medicine trials-NCI MATCH and MPACT

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

ROS1 rearrangements define a unique molecular class of lung cancers.

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

P304

39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FMED.2017.00039

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28443282

http://www.w3.org/2001/XMLSchema#string

P932

5385461

http://www.w3.org/2001/XMLSchema#string